LEADER 04467nam 2200709 450 001 9910717355303321 005 20221105201948.0 035 $a(CKB)4330000000505680 035 $a(NjHacI)994330000000505680 035 $a(CaOOCEL)10063317 035 $a(OCoLC)897023740$z(OCoLC)1117910941 035 $a(OCoLC)1000916263 035 $a(VaAlCD)20.500.12592/22ntq3 035 $a(EXLCZ)994330000000505680 071 60$a10063317$bCaOOCEL$q(Public Documents) 100 $a20221105d2013 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aScreening pelvic examinations in asymptomatic average risk adult women /$fAndrew Olson [and six others] editors 210 1$aWashington (DC) :$cCanadian Task Force on Preventive Health Care,$d[2013] 210 4$dİ2013 215 $a1 online resource (iii, 50 pages) $cillustrations 300 $a"Evidence-based synthesis program." 300 $a"September 2013." 320 $aIncludes bibliographical references. 330 3 $aThe routine pelvic examination has been a usual part of preventive care for women for many decades. In 2008, 63.4 million pelvic examinations were performed in the United States. Many women and providers believe that the routine pelvic exam should be included in an annual comprehensive well-woman visit.^The exam consists of inspection of the external genitalia, speculum examination of the vagina and cervix, bimanual examination, and sometimes rectal or rectovaginal examination.^Traditionally, the examination in the asymptomatic average risk women has been used to screen for pathology through palpation, visualization, and specimen collection.^Pathology potentially detectable on the pelvic examination includes malignancies (e.g., cervical, ovarian, uterine, bladder, vaginal or vulvar); infections (e.g., Chlamydia, gonorrhea, warts, candidiasis, bacterial vaginosis); pelvic inflammatory disease (PID); or other pathology (e.g., atrophic vaginitis, cervical polyps, uterine prolapse, fibroids). In addition, pelvic examinations are often performed prior to the provision of hormonal contraception.^Recent high quality evidence-based reviews and guidelines have concluded that pelvic examinations are not required for Chlamydia and gonorrhea screening or for hormonal contraception initiation and up-to-date evidence-based guidelines for cervical cancer screening are also available.^However, we are unaware of any systematic reviews that have investigated the utility of the pelvic examination for the other indications.^This systematic review was undertaken to evaluate the benefits and harms of the routine screening pelvic examination in asymptomatic, average risk, non-pregnant, adult women. For cervical cancer and sexually transmitted infection (i.e., Chlamydia and gonorrhea) screening and for initiation of hormonal contraception we summarize the results of recent reviews and guidelines from major US health organizations. For all other indications, we performed and report results from a comprehensive search of the medical literature. 606 $aCa-125$2Iptcnc 606 $aCancer$2Iptcnc 606 $aCancer screening$2Iptcnc 606 $aCervical cancer$2Iptcnc 606 $aCervical screening$2Iptcnc 606 $aCervix$2Iptcnc 606 $aChlamydia infection$2Iptcnc 606 $aClinical medicine$2Iptcnc 606 $aEvidence-based medicine$2Iptcnc 606 $aGonorrhea$2Iptcnc 615 7$aCa-125 615 7$aCancer 615 7$aCancer screening 615 7$aCervical cancer 615 7$aCervical screening 615 7$aCervix 615 7$aChlamydia infection 615 7$aClinical medicine 615 7$aEvidence-based medicine 615 7$aGonorrhea 676 $a618.1 700 $aBloomfield$b Hanna E.$01353456 702 $aOlson$b Andrew 712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service, 712 02$aQuality Enhancement Research Initiative (U.S.) 712 02$aMinneapolis VA Health Care System (U.S.).$bVA Evidence Synthesis Program. 712 02$aEvidence-based Synthesis Program (U.S.) 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910717355303321 996 $aScreening pelvic examinations in asymptomatic average risk adult women$93498643 997 $aUNINA